GB2527591A — 7-hydroxy cannabidiol (7-OH-CBD) for use in the treatment of non-alcoholic fatty liver disease (NAFLD)

USPTO Abstract

The liver plays a key role in regulating total body energy homeostasis and its ability to do so is greatly affected by the occurrence of pathological conditions such as hepatosteatosis or non-alcoholic fatty liver disease (NAFLD), which contributes to hepatic insulin resistance and potentially end-stage liver disease-related mortality. Triglyceride accumulation in hepatocytes of steatolic livers results from the incorporation of plasma free fatty acids as well as de novo fat synthesis. The present invention provides 7-hydroxy-cannabidiol (7-OH-CBD) for use in the treatment of non-alcoholic fatty liver disease (NAFLD). Preferably the treatment involves lowering triglyceride levels in a patients blood stream, wherein the high triglyceride levels may be caused by obesity, type II diabetes or medication. The dose of 7-OH-CBD is preferably between 1 and 1000mg/kg day. A pharmaceutical formulation comprising 7-OH-CBD and one or more excipients wherein the 7-OH-CBD may be used in combination with another medicament either separately, sequentially or simultaneously or provided within a single dosage form is outlined.